Spatial and Spatio-temporal Epidemiology

Spatial and Spatio-temporal Epidemiology - ISSN 1877-5845
Source Normalized Impact per Paper (SNIP): 0.661 Source Normalized Impact per Paper (SNIP):
SNIP measures contextual citation impact by weighting citations based on the total number of citations in a subject field.
SCImago Journal Rank (SJR): 0.622 SCImago Journal Rank (SJR):
SJR is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and a qualitative measure of the journal’s impact.
Volumes: Volume 4
Issues: 4 issues
ISSN: 18775845
Editor-in-Chief: Lawson

Personal Subscription

Sales tax will be calculated at check-out Price includes VAT/GST

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.


Spatial and Spatio-Temporal Epidemiology is a peer-reviewed scientific journal that provides a home for high quality work which straddles the areas of GIS, epidemiology, exposure science, and spatial statistics. The journal focuses on answering epidemiological questions where spatial and spatio-temporal approaches are appropriate. The methods should help to advance our understanding of infectious and non-infectious diseases in humans.

The journal will also consider applications where health care provision is the focus. Coverage of veterinary topics will be included, and those with direct human health implications are especially welcome. The journal places special emphasis on spatio-temporal aspects of emerging diseases (e.g. COVID-19, avian flu, SARS), development of spatial statistical and computational methods, and novel applications of geospatial technology (e.g., GPS, GIS) for shedding insights on exposure and disease processes.

The journal accepts three different types of submissions:

  1. Methods papers that outline new methodology in the areas of GIS, spatial statistics, exposure science, and/or epidemiology;
  2. Case Study/Applications papers where recently developed methodology is applied to novel applications with a clear exposure/disease focus; and
  3. Short reports where a) they are around 4-8 text pages in length b) they focus on an important novel development and c) the development should be capable of description within the page length. Case Studies progress reports in the form of 'what we have done so far' are not acceptable as Short Reports unless they comply with b) or c) above.